Source:http://linkedlifedata.com/resource/pubmed/id/15094754
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2004-6-8
|
| pubmed:abstractText |
We conducted a nationwide survey to define incidence of deep fungal infections and fungal prophylaxis practices after HSCT. In all, 63 institutions responded. Total number of in-patient transplantations was 935: 367 autologous, 414 allogeneic myeloablative, and 154 allogeneic reduced-intensity (RIST) (n=154). Number of patients who were cared for in a clean room at transplant was 261 (71%) in autologous, 409 (99%) in conventional and 93 (66%) in RIST, respectively. All patients received prophylactic antifungal agents; 89% fluconazole. Number of patients who received the dosage recommended in the CDC guidelines (400 mg/day) was 135 (42%) in conventional transplant and 34 (30%) in RIST (P=0.037). Number of patients who received fluconazole until engraftment and beyond day 75 in conventional transplant vs RIST was, respectively, 324 (100%) vs 109 (97%), and 39 (12%) vs 18 (16%), with no significant difference between the two groups. A total of 37 patients (4.0%) were diagnosed with deep fungal infections; autologous transplantation (0.03%), conventional transplantation (6.0%) and RIST (7.1%). Wide variations in antifungal prophylaxis practice according to the type of transplant and the institutions, and deep fungal infection remain significant problems in RIST.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AdachiYY,
pubmed-author:AnanKK,
pubmed-author:FukuharaTT,
pubmed-author:GotohMM,
pubmed-author:HamaguchiMM,
pubmed-author:HashinoSS,
pubmed-author:HiguchiMM,
pubmed-author:ImatakaGG,
pubmed-author:InoueTT,
pubmed-author:KammII,
pubmed-author:KasaiMM,
pubmed-author:KawakamiKK,
pubmed-author:KimS-WSW,
pubmed-author:KobayashiYY,
pubmed-author:KomabaSS,
pubmed-author:MasudaMM,
pubmed-author:NaitoKK,
pubmed-author:NishimuraMM,
pubmed-author:TakaueYY,
pubmed-author:TeshimaHH,
pubmed-author:TogitaniKK,
pubmed-author:UikeNN,
pubmed-author:YamashitaTT
|
| pubmed:issnType |
Print
|
| pubmed:volume |
33
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1173-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15094754-Antifungal Agents,
pubmed-meshheading:15094754-Data Collection,
pubmed-meshheading:15094754-Fluconazole,
pubmed-meshheading:15094754-Hematologic Diseases,
pubmed-meshheading:15094754-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15094754-Humans,
pubmed-meshheading:15094754-Incidence,
pubmed-meshheading:15094754-Japan,
pubmed-meshheading:15094754-Mycoses,
pubmed-meshheading:15094754-Practice Guidelines as Topic,
pubmed-meshheading:15094754-Premedication,
pubmed-meshheading:15094754-Retrospective Studies,
pubmed-meshheading:15094754-Transplantation, Autologous,
pubmed-meshheading:15094754-Transplantation, Homologous,
pubmed-meshheading:15094754-Transplantation Conditioning
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan.
|
| pubmed:affiliation |
Hematopoietic Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|